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ABSTRACT
Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease.
Previous research has shown that antecedent conditions are less prevalent in ALS patients
than the general population. Current research has suggested some conditions are
protective against ALS. The purpose of this study is to examine the relationship between
antecedent conditions and ALS, using age of diagnosis and disease duration.
Methods: Patient data was obtained through the Emory ALS Clinic in Atlanta, Georgia.
Patients’ histories were analyzed to see if they had any antecedent conditions (high blood
pressure, high cholesterol, diabetes, obesity, asthma, arthritis, COPD, kidney disease,
liver disease, non-ALS neurological disease, and thyroid disease) at their time of
diagnosis. Patients with antecedent conditions compared with the control population
(ALS patients without any antecedent diseases) are analyzed through chi square test to
see the distributions on age of diagnosis and disease duration. Ordinal logistical
regression modelling was completed to see the magnitude of effect antecedent conditions
has on disease duration and age of diagnosis.
Results: All antecedent conditions had an older age at ALS diagnosis than the control
population except obesity, kidney disease, and liver disease (p<0.05). Disease duration
was found to be significantly shorter compared to the control population when looking at
high blood pressure, diabetes, obesity, arthritis, and kidney disease (p<0.05). When
looking at the antecedent conditions as a whole, those with cardiovascular diseases, or
between 1 and 3 diseases, had a very significant older age of diagnosis (p<0.0001), and a
significant shorter disease duration (p<0.05).
Conclusions: Antecedent conditions high blood pressure, high cholesterol, and COPD can
be seen as protective against ALS due to their delayed age of diagnosis. A possible
explanation is that these antecedent diseases could be biochemically neuroprotective
against ALS in a currently unknown pathway. Antecedent disease association, with
reduced disease duration, is likely due to the advanced age of the patient.
KEYWORDS
amyotrophic lateral sclerosis, antecedent condition, disease duration, diagnosis age,
prognosis, high blood pressure, hypertension, high cholesterol, hyperlipidemia,
dyslipidemia, obesity, diabetes, asthma, arthritis, COPD, chronic obstructive pulmonary
disease, thyroid, kidney, liver
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Chapter I

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a debilitating neuromuscular disease that
affects almost 4 in 100,000 people in the United States (Mehta et al., 2014). Those
afflicted with the disease face losing control over major muscle groups such as arms,
legs, and core muscles including their diaphragm. Only 5 to 10% of ALS is attributed to a
familial gene; the majority is considered idiopathic (Andersen, 2000).
Previous research on ALS shows a link connection those without common
conditions having ALS (Korner et al., 2013; Mitchell et al., 2015). These common
conditions, such as elevated blood pressure, high cholesterol, obesity, and diabetes were
found to be less prevalent in the ALS population than a control population (Dorst et al.,
2011; Dupuis et al., 2008; Korner et al., 2013; Mitchell et al., 2015).
Current literature suggests the association of certain factors, like age at diagnosis
and gender of the patient, may lead to shorter disease duration in patients diagnosed with
ALS. Emerging research now links several common conditions to either having no effect
or lengthening disease duration. However, literature has not yet been able to fully explore
the effects of these factors and common conditions on the patients’ age at diagnosis. This
is an important factor as the younger an individual is at time of ALS diagnosis, the longer
the disease duration will be (Wei et al., 2015; Wolf et al., 2014).
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Chapter II

LITERATURE REVIEW

Overview
Amyotrophic lateral sclerosis (ALS) is a debilitating neurological disease that
attacks the motor neurons. As of 2011, it affects nearly 4 per 100,000 people in the
United States as of 2011 (Mehta et al., 2014). The cause of ALS is largely attributed to
being idiopathic, with less than 10 percent being related to a familial gene. (Andersen,
2000).
Prior to an ALS diagnosis, many patients consider themselves to be healthier than
the general population (Turner, 2013). Some research has shown lifelong athletes having
a higher risk of developing ALS than non-athletes (Chio et al., 2009). ALS does not
directly relate to having an active lifestyle, but factors that are associated with an active
lifestyle also lead to an increase in ALS susceptibility (Beghi, 2013; Huisman et al.,
2013; Valenti et al., 2005).
Current research is seeking to improve longevity after a patient receives a
diagnosis of ALS. The only FDA-approved treatment, Riluzole, has been shown to
improve longevity, but only when taken within the first 6 months of therapy (Cetin et al.,
2015). Common factors related t0 disease duration are age at onset, gender, and race
(Jawaid, Murthy, et al., 2010; Korner et al., 2013; Watanabe et al., 2014; Wolf et al.,
2014).
This study will attempt to analyze the relationship between many antecedent
conditions and the disease duration and diagnosis age of ALS. More specifically, these
conditions include cardiovascular (including hypertension, hyperlipidemia, obesity, and
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diabetes), autoimmune (asthma, chronic obstructive pulmonary disease [COPD], thyroid
disease, and arthritis), non-ALS neurological disease, kidney disease, and liver diseases.
These diseases are of interest when they manifest in the patient prior to ALS diagnosis.
Epidemiology of Amyotrophic Lateral Sclerosis
Disease Duration
The average life expectancy of ALS patients is currently less than two years after
diagnosis (Cetin et al., 2015). Researchers are looking at many variables in order to help
give patients a more accurate prognosis. Currently known and accepted factors for
survival include age at diagnosis, gender, body weight at diagnosis, and interval between
onset and diagnosis (Gil et al., 2007; Wei et al., 2015; Wolf et al., 2014).
One line of current research is how concurrent illness in ALS patients affects
disease duration (Korner et al., 2013; Moreau et al., 2012; Paganoni, Deng, Jaffa,
Cudkowicz, & Wills, 2011). While some studies have found that common conditions;
such as hyperlipidemia and diabetes did not affect the length of survival (Dedic et al.,
2012; Korner et al., 2013; Sutedja et al., 2011), other studies found that the common
conditions did have a positive of negative effect (Moreau et al., 2012; Paganoni et al.,
2011). Lung ability, (e.g. full vital capacity and maximal inspiratory capacity), was
found to be an accurate predictor for disease duration (Schmidt et al., 2006). Uric acid
and tauroursodeoxycholic (TUDCA) acid, a hydrophilic bile, have also been linked with
a prolonged survival in ALS patients (Elia et al., 2015; Paganoni et al., 2012). There are
currently no studies that have successfully demonstrated a link between ALS disease
duration and other non-ALS neurological diseases.

Age of Diagnosis Models
An accepted variable to predict disease duration in ALS patients is age at
diagnosis; however, the age at which an individual will be diagnosed cannot be predicted.
Within the general population, ALS increases in prevalence with increasing age, reaching
a peak at the 60-69 age range (Mehta et al., 2014). Research supports the stance that
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ethnicity has a role in the age of diagnosis, as those with Asian race are found to be
diagnosed at an earlier age than Caucasians (Wei et al., 2015).
Comparing age of diagnosis with antecedent conditions, diabetes mellitus type 2
is found to be correlated with a later onset of 4 years compared to those without diabetes,
adjusting for gender, ethnicity, and site of onset (Jawaid, Salamone, et al., 2010). Body
mass index (BMI) at time of diagnosis was not found to have an association with age of
onset (Jawaid, Murthy, et al., 2010).

Antecedent Conditions of Interest
Cardiovascular Conditions
For this study, cardiovascular conditions of interest include hyperlipidemia (high
cholesterol), hypertension (high blood pressure), obesity (BMI greater than or equal to
30.0), and diabetes mellitus (both type 1 and type 2). Many studies have examined these
cardiovascular diseases within the same population but the effects of combinations of
these diseases are relatively unstudied (Korner et al., 2013; Mitchell et al., 2015).


Hyperlipidemia – Hyperlipidemia is a commonly studied antecedent condition
among ALS patients. Some studies have found that the presence of
hyperlipidemia can extend the length of survival after diagnosis (Dedic et al.,
2012; Dorst et al., 2011; Dupuis et al., 2008; Sutedja et al., 2011). Other studies
have found hyperlipidemia to not be related to disease duration (Korner et al.,
2013; Paganoni et al., 2011; J. W. Yang et al., 2013).



Hypertension – In research, hypertension has shown a mixed association with the
disease duration in ALS patients. Relating to effect on disease duration,
hypertension has been shown to be beneficial (Sutedja et al., 2011), neutral
(Korner et al., 2013), and detrimental (Moreau et al., 2012).



Diabetes – In ALS patients, diabetes is less prevalent than the general population
(Mariosa, Kamel, Bellocco, Ye, & Fang, 2015; Mitchell et al., 2015). Research
has also shown patients with diabetes to have a 4 year later onset of ALS
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compared to ALS patients without diabetes (Jawaid, Salamone, et al., 2010).
However, it also has been shown to not have any effect on survival length (Korner
et al., 2013).


Obesity – Obesity is primarily studied in regards to the BMI calculation itself, not
the categories affected by BMI. Studies have shown that those with a lower BMI,
between 18.5 and 24.9 or the ‘healthy’ range, are found to be at a higher risk of
ALS than individuals with a higher BMI (Mitchell et al., 2015; O'Reilly et al.,
2013). Survival models have shown that a slower rate of change in BMI after
diagnosis is related to longer disease duration (Jawaid, Murthy, et al., 2010;
Paganoni et al., 2011; Sutedja et al., 2011).

Autoimmune Conditions
Autoimmune conditions of interest include asthma, COPD, arthritis, and thyroid
disease. Some studies have found that these conditions are found at a higher prevalence
in the ALS population compared to the general population (Turner, Goldacre,
Ramagopalan, Talbot, & Goldacre, 2013). However, other studies have found these
conditions are at a lower prevalence (Mitchell et al., 2015). These conditions can be
related to pulmonary function, which is found to be a direct predictor of disease duration
in ALS patients (Schmidt et al., 2006). Autoimmune therapies have been shown to help
slow the progression of ALS, as there are similar pathways that lead to the development
of autoimmune diseases and ALS (Alexianu, 1995; Schulte-Herbruggen, Braun,
Rochlitzer, Jockers-Scherubl, & Hellweg, 2007; E. J. Yang et al., 2010)

Other Conditions
Kidney and liver diseases have not been extensively studied in ALS populations,
but have been found to be less prevalent when compared to the general population
(Mitchell et al., 2015). Uric Acid, which can be an indicator of kidney function, was
found to be associated with longer disease duration in male ALS patients (Johnson et al.,
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2013; Paganoni et al., 2012). TUDCA (a hydrophilic bile in the liver) has been shown in
a pilot study to improve the ALSFRS-R (ALS functional ratings scale) scores (Elia et al.,
2015).
Neurological diseases, such as dementia and Parkinson’s, have conflicting
associations with ALS. These range from being more common in ALS patients compared
to general population, or not being related to the ALS diagnosis, to being less prevalent
(Korner et al., 2013; Mitchell et al., 2015; van Doormaal et al., 2013). Multiple Sclerosis
is one neurologic disease with research indicating such a correlation (Etemadifar, Abtahi,
Akbari, & Maghzi, 2012) and there being no correlation (van Doormaal et al., 2013)
within ALS patients.

Previous Research
The ALS patients included in this study have previously been examined for the
prevalence of common conditions relative to the general population (Mitchell et al.,
2015). The population of 1288 patients were examined for multiple pre-existing
conditions, then matched with a control population based age, gender, and geographic
region. The pre-existing conditions studied include hypertension, hyperlipidemia,
diabetes, obesity, asthma, arthritis, COPD, thyroid disease, liver disease, non-ALS
neurological disease, and kidney disease.
Results showed that the ALS patients had lower prevalence of all diseases of
interest when age, gender, and spatially matched to the general population. The ALS odds
of arthritis (OR = 0.14), non-ALS neurological disease (OR = 0.14), liver disease (OR=
0.19), chronic obstructive pulmonary disorder or COPD (OR = 0.23), kidney disease (OR
= 0.32), adult asthma (OR = 0.39), diabetes (OR = 0.47), hypertension (OR = 0.56),
obesity (OR = 0.6), hyperlipidemia or hypercholesterolemia (OR = 0.62), and thyroid
disease (OR = 0.78) were lower than the odds of those in the general population. See
Table A for the 95% confidence intervals.
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There are two pathways to explain the lower prevalence. One method is “Other
condition as ALS protection”, where the presence of antecedent conditions is protective
against ALS. This could through a currently unknown biochemically neuroprotective
pathway. Another explanation is “ALS as other condition protection” where the ALS
disease interferes with the underlying causes of the antecedent conditions.
Table A. Associations of ALS with odds of antecedent conditions. Parameters are oddsratio (OR) and 95% confidence interval (CI). The prevalence of each condition is less in
ALS compared to the age and gender ratio-matched control condition
Condition

Odds Ratio, (95%
Confidence Interval)

Arthritis

0.14, (0.11, 0.18)

Neurological
Disease

0.14, (0.07, 0.27)

Liver Disease

0.19, (0.10, 0.35)

COPD

0.23, (0.16, 0.32)

Kidney Disease

0.32, (0.18, 0.57)

Asthma

0.39, (0.30, 0.51)

Diabetes

0.47, (0.38, 0.58)

Hypertension

0.56, (0.49, 0.64)

Obesity

0.60, (0.49, 0.74)

Hyperlipidemia

0.62, (0.54, 0.71)

Thyroid Disease

0.78, (0.60, 1.02)

Purpose of Research
There are several different factors that have been examined individually for their
effect on the prognosis in those with ALS, with some examining a larger array of
conditions. This study will analyze the relationships between individual conditions and
ALS patients. The conditions will also be analyzed together on ALS disease duration and
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age of diagnosis to see if there is any interaction within the antecedent conditions.
Logistic regression will be done to shed light on possible factors for age of diagnosis,
along with clarifying the impact the antecedent conditions have. This will help clarify
avenues for future research to understand underlying causes of ALS along with possible
areas to focus when creating new treatments.

Chapter III

Abstract

Background: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease.
Previous research has shown that antecedent conditions are less prevalent in ALS patients
than the general population. Current research has suggested some conditions are
protective against ALS. The purpose of this study is to examine the relationship between
antecedent conditions and ALS, using age of diagnosis and disease duration.
Methods: Patient data was obtained through the Emory ALS Clinic in Atlanta, Georgia.
Patients’ histories were analyzed to see if they had any antecedent conditions (high blood
pressure, high cholesterol, diabetes, obesity, asthma, arthritis, COPD, kidney disease,
liver disease, non-ALS neurological disease, and thyroid disease) at their time of
diagnosis. Patients with antecedent conditions compared with the control population
(ALS patients without any antecedent diseases) are analyzed through chi square test to
see the distributions on age of diagnosis and disease duration. Ordinal logistical
regression modelling was completed to see the magnitude of effect antecedent conditions
has on disease duration and age of diagnosis.
Results: All antecedent conditions had an older age at ALS diagnosis than the control
population except obesity, kidney disease, and liver disease (p<0.05). Disease duration
was found to be significantly shorter compared to the control population when looking at
high blood pressure, diabetes, obesity, arthritis, and kidney disease (p<0.05). When
looking at the antecedent conditions as a whole, those with cardiovascular diseases, or
between 1 and 3 diseases, had a very significant older age of diagnosis (p<0.0001), and a
significant shorter disease duration (p<0.05).
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Conclusions: Antecedent conditions high blood pressure, high cholesterol, and COPD can
be seen as protective against ALS due to their delayed age of diagnosis. A possible
explanation is that these antecedent diseases could be biochemically neuroprotective
against ALS in a currently unknown pathway. Antecedent disease association, with
reduced disease duration, is likely due to the advanced age of the patient.

Introduction
Amyotrophic lateral sclerosis (ALS) is a debilitating neurodegenerative disease
with a relatively unknown etiology. Many times, those diagnosed with ALS have
previously led healthy and active lifestyles (Huisman et al., 2013; Turner, 2013).
Researchers have looked at multiple antecedent conditions to see if there is any link
between these conditions and ALS, yet there have been no conclusive results (Dedic et
al., 2012; Etemadifar et al., 2012; Jawaid, Salamone, et al., 2010; Korner et al., 2013;
Paganoni et al., 2012). Only 5 to 10 percent of the ALS population can be attributed to
genetic factors (Andersen, 2000) while the rest are idiopathic.
Existing research has found several factors that impact disease duration and age of
onset of ALS in patients. Onset age has been found to occur earlier in those of Asian
race, or male gender (Watanabe et al., 2014; Wei et al., 2015). Shorter disease duration is
related to patients that have a more advanced age at onset of ALS symptoms (Gil et al.,
2007; Jawaid, Murthy, et al., 2010; Watanabe et al., 2014).
When looking at antecedent conditions, it has been shown that the ALS patients
have lower rates than that of the general public (Korner et al., 2013; Mitchell et al.,
2015). These lower rates have led to speculation that the conditions could act as
protection against ALS, possibly due to the hyper-metabolic state found in ALS patients
(Jawaid, Salamone, et al., 2010).
The effect of these conditions have been shown to have a positive (Dorst et al.,
2011; Moreau et al., 2012; Paganoni et al., 2012), neutral (Dedic et al., 2012; Korner et
al., 2013), or negative (Jawaid, Murthy, et al., 2010) effect on duration of ALS in
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patients. The effect on age at diagnosis is more consistent when studied, and shows a
delayed age of diagnosis (Jawaid, Salamone, et al., 2010; Korner et al., 2013).
This study will focus on how multiple types of antecedent conditions (high blood
pressure, high cholesterol, diabetes, obesity, asthma, arthritis, COPD [Chronic
Obstructive Pulmonary Disease], thyroid disease, kidney disease, liver disease, and nonALS neurological disease) effect ALS through diagnosis age and disease duration.
Methods
A case control study of antecedent conditions on diagnosis age and disease
duration of an ALS population was performed. The ALS population consisted of 1439
patients from the Emory ALS Clinic, in Atlanta Georgia confirmed to have ALS at their
first clinic visit. The Internal Review Boards of Emory University, Georgia Institute of
Technology, and Georgia State University approved all protocols of this study.

Antecedent Conditions
The prevalence of high blood pressure, high cholesterol, diabetes, obesity,
arthritis, asthma, COPD, thyroid disease, neurological disease (excluding ALS), kidney
disease and liver disease were assessed at the first visit by medical personnel and a selfcompleted patient entry survey. Additional information for gathering the data can be seen
in a previously published paper (Mitchell et al., 2015).

Study Populations
Two study populations were identified from the ALS clinic population. Control
population was determined by the confirmed ALS patients having no antecedent
conditions of interest at their first visit. The antecedent conditions population was
determined by the ALS patients having at least one of the following: high blood pressure,
high cholesterol, diabetes, obesity, arthritis, asthma, COPD, thyroid disease, neurological
disease, kidney disease, or liver disease, at their first visit.
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These study populations were then analyzed to see if they met the qualifications
of the two groups of interest. All patients were included in Group 1(n=1349). Group 1
included patients with a confirmed diagnosis age. Those with a date of death in their
medical records were also placed in Group 2 (n=787). Group 2 was used to analyze
disease duration with ALS patients.

Statistical Analysis
All statistical tests were completed using SAS 9.3. Chi square analysis was done
to compare the distributions of the control population and antecedent disease population
for both outcomes of interest. For age of diagnosis, the chi square compared the
distribution above and below the mean age of diagnosis of the entire population. For the
length of survival, the chi square compared the distribution above and below the mean
length of survival of the subset of the total population. The distributions were compared
between the control group and the antecedent disease group for both the age of diagnosis
and survival length.
Ordinal logistic regression was completed for both age of diagnosis and length of
survival to assess for confounders and compare the antecedent diseases with known risk
factors. This was done to examine what extent each of the antecedent diseases and other
factors related to the age of diagnosis and survival length.
For both models, male gender and Caucasian race were set as the reference
group. Race was assessed as Caucasian, African American, and Other. The ordinal
logistic regression for age of diagnosis included all antecedent diseases, race, and gender.
The ordinal logistic regression for length of survival included all antecedent diseases,
race, gender, and age of diagnosis.
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Results
Demographics
Group 1, consisting of those who had a confirmed ALS diagnosis, is 60% male
and 40% female, with 57% of the population having at least one antecedent condition.
Group 2, those who had a confirmed ALS diagnosis and date of death, is 57.7% male and
42.3% female, along with 54% having at least one antecedent condition. Gender falls on
a more equal distribution in group 2 than group 1(p<0.05). All of the antecedent
conditions except high cholesterol, diabetes, and obesity occur within the same
distribution between both population groups. (See Table 1 for additional demographic
information)
Group 1, those with a confirmed ALS diagnosis, has a diagnosis age mean of 60.1
years with a standard deviation of 12.5 years. The mean diagnosis age among the control
population was 56.6 years; males at 54.5 and females at 59.1 years of age. Those with
antecedent disease had an average of 63.1 years; males at 62.4 years and females at 64.1
years of age. A substantially greater proportion of individuals with antecedent conditions
are older when compared to those without antecedent conditions of interest (p<0.0001).
Group 2 has average disease duration of 2.1 years with a standard deviation of 2.1
years. Those without antecedent conditions of interest have an average of 2.4 years; with
males at 2.5 and females at 2.4 years of survival. Those with antecedent conditions have
disease duration of 1.9 years; with males at 2.0 and females at 1.7 years of survival. The
antecedent condition group had a substantially shorter disease duration when compared
with those without antecedent conditions (p<0.0001).

Chi Square Analysis
Chi Square test was used to compare age of diagnosis and disease duration
between antecedent conditions and those without any antecedent conditions. Antecedent
condition populations include: Sole condition (only having one antecedent condition of
interest), Multiple condition (having multiple antecedent conditions including the
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condition of interest), Cardiovascular (having any number of the following: High blood
pressure, High cholesterol, Diabetes, or Obesity), Autoimmune (having any of the
following: Asthma, Arthritis, COPD, Thyroid disease), and finally Amount (the number
of any antecedent conditions present). For example, a patient with the conditions of
diabetes and asthma would be located in the Multiple condition group for asthma and for
diabetes, the cardiovascular group, the autoimmune group, and the Amount group of 2.
Sole and Multiple condition populations are found in Table 2. Cardiovascular,
Autoimmune, and Amount populations are found in Table 3. Mean age of diagnosis and
disease duration of the antecedent condition populations are reported along with the
number of patients analyzed for that comparison within the tables.
Age of Diagnosis
High blood pressure and high cholesterol are found to have a substantially
significant older distribution than the control ALS population as Sole antecedent
condition, or Multiple antecedent condition (p<0.0001). A significant later age of
diagnosis distribution is also found for diabetes, asthma, arthritis, COPD, thyroid
diseases, and non-ALS neurological diseases, in Multiple antecedent condition groups
(p<0.05).
In the cardiovascular group, substantial significance for a later age of diagnosis
distribution is found for all categories except the four cardiovascular conditions group
(p<0.001). Autoimmune conditions only show substantial significance when other
antecedent diseases are involved for having a later age of diagnosis distribution than the
control (p<0.0001).
Up to three antecedent condition groups have a substantially significantly older
distribution (p<0.0001). Those with four antecedent conditions have a significant older
distribution at diagnosis (p<0.05). There is no significance found for those with five or
six antecedent conditions.
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Disease Duration
High blood pressure, high cholesterol, diabetes, obesity, arthritis and kidney
disease all have a different distribution than the control for Multiple antecedent
conditions (p<0.05). The significance found shows that those antecedent condition
populations have a shorter disease duration that the control population.
Cardiovascular conditions show significance for disease duration for one, two,
and three conditions or having any cardiovascular condition at all (p<0.005). Those
categories are correlated to a shorter disease duration when compared to the control
population.
Amount antecedent conditions of one, two, and three results in a substantially
shorter disease duration than the control (p<0.0005). Significance is not found in those
with four, five, or six antecedent conditions due to a limiting sample size.

Ordinal Logistical Regression
Ordinal logistical regression modelling is used for age of diagnosis and disease
duration. High blood pressure, high cholesterol, COPD, ‘Other’ race, and gender were
found to be significant variables with an association to a delayed the age of diagnosis past
the mean (60.1 years). ‘African American’ race and obesity are found to have a
significant association to an earlier age of diagnosis. When looking at disease duration,
age of diagnosis and ‘Other’ race are significant variables associated with shortening
disease duration under the mean (2.1 years). ‘African American’ race has a significant
association with lengthening disease duration beyond the mean. See Table 4 for the odds
ratios for all variables tested.
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Other Results
The population was gender stratified to look for additional patterns. Significance
results mirror that of the overall population for both genders. Antecedent conditions were
also analyzed with permutations of two antecedent conditions. Significance is only found
in the more prevalent condition permutations, such as high blood pressure and high
cholesterol, where a large sample size is present. Any significance is reflected in the
grouping of diseases.

Discussion
Results of the chi square analysis indicates an overall pattern that those with
antecedent conditions have a later age of diagnosis, and shorter disease duration, than
those without antecedent conditions within the ALS population. When controlled for
confounders, only high blood pressure, high cholesterol, obesity, and COPD are found to
be significant factors in diagnosis age.

Antecedent Conditions on Age of Diagnosis
When looking at individual antecedent conditions, every condition of interest is
found to have a later age of diagnosis excluding obesity (see What about Obesity?). High
blood pressure, high cholesterol, and COPD are found to be significant factors in
delaying the age of diagnosis. These conditions have also been found to be less prevalent
in the ALS population (Korner et al., 2013; Mitchell et al., 2015; Sutedja et al., 2011).
With the prevalence lower in the ALS population, there may be a mechanism in
which these antecedent conditions are protective against ALS in an unknown pathway.
Diabetes and high cholesterol have been previously suggested to be biochemically
neuroprotective against ALS (Dupuis et al., 2008; Jawaid, Salamone, et al., 2010).
ALS could possibly develop due to hypervigilance of the body’s systems, which
can be seen with hyper-metabolism in patients, which could also explain the delayed
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onset (Desport, Torny, Lacoste, Preux, & Couratier, 2005; Jawaid, Salamone, et al.,
2010; J. W. Yang et al., 2013). If the body has a lower level of hypervigilance, it would
allow these antecedent conditions to form (Mitchell et al., 2015). The less severe
hypervigilance would, as a separate function, cause ALS to develop at a later age. Those
with a higher level of hypervigilance would not develop antecedent conditions, but would
develop ALS at an earlier age.

Antecedent Conditions on Disease Duration
No antecedent conditions are found to be significant factors in predicting the
disease duration in patients. Some researchers have found that cardiovascular conditions
are beneficial to ALS patients as ALS progresses (Dorst et al., 2011; Dupuis et al., 2008),
but further research supports that the conditions do not have a significant impact on ALS
disease duration (Dedic et al., 2012; Korner et al., 2013; Paganoni et al., 2011).
The shorter disease duration found in the antecedent condition groups can be
attributed to the fact that those groups have a later age of diagnosis. Advanced age is
known to be a predictor of shorter disease duration (Gil et al., 2007; Watanabe et al.,
2014). Antecedent conditions are found more in older patients whether due to the
condition protecting against ALS, or the prevalence of the conditions increasing with age.

What about Obesity?
Obesity is the only antecedent condition found to be a significant predictor of a
younger age of diagnosis. Many studies show that obesity can be beneficial to ALS
patients in terms of survival (Jawaid, Murthy, et al., 2010; Shimizu et al., 2012). Other
research has found obesity to be less prevalent in ALS patients than the general
population (Mitchell et al., 2015; O'Reilly et al., 2013; Paganoni et al., 2011). While
these results (shorter disease duration) appear to be conflicting, further understanding of
how the variables were defined is needed.
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When obesity is found to be beneficial to survival, the variable measured is the
rate of change in BMI (Jawaid, Murthy, et al., 2010; Shimizu et al., 2012). Other studies
have focused on unhealthy weight, taking any BMI above 24.9 to be considered of
interest, with the effects varying as BMI changes (O'Reilly et al., 2013; Paganoni et al.,
2011).
Our measure of obesity is a BMI greater than or equal to 30.0 at the time of
diagnosis and change in BMI is not reflected in our study. Obesity likely has multifaceted
implications on the disease duration and diagnosis of ALS that cannot be interpreted with
this broad and static definition used.

Limitations
One limitation is lack of complete demographic information. Many
patients did not have a race in their records, or declined to give their race. This resulted
grouping a large portion of the patients into the ‘Other’ race category. Sample size is also
a limitation throughout the study. Despite the large overall population used, less than 25
individuals are found to have thyroid disease, kidney disease, liver disease, or non-ALS
neurological disease. A larger population of ALS patients with these antecedent
conditions would allow for more accurate results.

Conclusion
Antecedent conditions, found less prevalent in ALS patients than the general
population, are also found to have an effect of the age of diagnosis. High blood pressure,
high cholesterol, and COPD are found to be significant factors associated in delaying the
age of diagnosis. Obesity was found to be a significant factor associated in an earlier age
of diagnosis, most likely due to an improper classification and its complex effects in ALS
patients. The delay of age of diagnosis among those with antecedent conditions could be
due to the hyper-metabolic or hyper-vigilant state present in ALS patients.
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Appendix A

Table 1. Demographics of Emory Clinic ALS population by Diagnosis Age and Disease Duration
Diagnosis Age Population
Overall
Control
Disease
1439
619
820

Population
Characteristics
N
Age

Disease Duration Population
Overall
Control
Disease
787
364
423

#ⱡ

mean (SD)
Survival Length
(years)
ⱡ
mean (SD)
Gender* %(N)

60.1 (12.5)

56.6(13.3)

63.1 (8.0)

61.2(12.4)

57.4 (13.2)

64.5 (10.6)

-

-

-

2.1 (2.1)

2.4 (2.3)

1.9 (1.8)

ⱡ

60.0 (864)

62.7 (388)

58.0 (476)

57.7 (454)

61.5 (224)

54.4 (230)

ⱡ

40.0 (575)

37.3 (231)

42.0 (344)

42.3 (333)

38.5 (140)

45.6 (193)

Caucasian
African American
Other
Antecedent
Conditions %(N)
High Blood Pressure

57.4 (826)
12.3 (177)
30.2 (434)

56.4 (349)
12.4 (77)
31.1 (193)

58.4 (479)
12.2 (100)
29.4 (241)

59.1 (465)
10.7 (84)
30.2 (238)

57.1 (208)
11.0 (40)
32.7 (119)

60.8 (257)
10.4 (44)
28.1 (119)

40.0 (532)

-

64.9 (532)

36.0 (283)

-

66.9 (283)

Male
Female
Race %(N)

46.1 (378) 24.0 (189)
High Cholesterol* 26.3 (378)
7.7
(111)
13.5
(111)
6.4
(50)
Diabetes*
9.0 (129)
15.7 (129)
7.1 (56)
Obesity*
Arthritis
5.1 (74)
9.0 (74)
5.0 (39)
Asthma
4.9 (71)
8.7 (71)
4.8 (38)
COPD
3.1 (45)
5.5 (45)
2.8 (22)
Thyroid
1.5 (22)
2.7 (22)
1.8 (14)
Neurological disease
0.8 (11)
1.3 (11)
1.0 (8)
Kidney Disease
0.8 (12)
1.5 (12)
1.3 (10)
Liver Disease
0.8 (12)
1.5 (12)
0.9 (7)
#
Age at first visit to clinic
*Age of Diagnosis population significantly different than Disease Duration Population (p<0.05)
ⱡ Control population significantly different than antecedent condition population (p<0.05)

44.7 (189)
11.8 (50)
13.2 (56)
9.2 (39)
9.0 (38)
5.2(22)
3.3 (14)
1.9 (8)
2.4 (10)
1.7 (7)
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Table 2. Antecedent Condition Effect of Age of Diagnosis and Disease Duration of ALS Population, Chi
Square Analysis
Age of Diagnosis
Mean (s.d)
N†
P-value
56.2 (13.3)
1439
<.0001

Population
Control*
Antecedent Condition
Blood pressure

Disease Duration
Mean (s.d)
N†
P-value
2.4 (2.3)
787
<.0001

Sole
Multiple

63.4 (10.5)
64.3 (10.5)

819
1151

<.0001
<.0001

1.9 (2.0)
1.8 (1.7)

481
647

0.0079
<.0001

Sole
Multiple

63.3 (10.4)
65.3 (10.2)

718
997

<.0001
<.0001

1.9 (1.5)
1.7 (1.5)

404
553

0.0612
<.0001

Sole**
Multiple

50.6 (12.8)
63.6 (10.1)

631
730

0.1410
<.0001

3.2 (3.3)
1.8 (1.8)

371
414

0.7035
0.002

Sole
Multiple

52.9 (9.6)
57.3 (11.1)

654
750

0.0185
0.3847

1.6 (0.9)
1.7 (1.2)

379
421

0.4646
0.0347

Sole
Multiple

56.0 (11.9)
61.1 (12.1)

641
690

0.4821
0.0367

3.0 (2.0)
2.3 (1.7)

377
402

0.1819
0.6881

Sole ‡
Multiple

60.3 (9.0)
65.6 (8.4)

638
693

0.2404
<.0001

2.3 (2.3)
1.8 (1.9)

373
403

0.7382
0.0379

Sole ‡
Multiple

60.4 (16.1)

0.2707
<.0001

2.7 (3.7)

64.3 (11.8)

634
664

1.9 (2.5)

370
386

1
0.5496

Multiple

67.4 (7.4)

641

0.0004

2.5 (2.1)

378

0.2899

Multiple**

68.7 (7.1)

630

0.0007

1.8 (2.1)

372

0.1457

Multiple**

69.4 (13.5)

631

0.0732

0.9 (0.6)

374

0.0063

Multiple**

56.0 (10.9)

631

0.3839

3.5 (3.5)

371

1

Cholesterol

Diabetes

Obesity

Asthma

Arthritis

COPD

Thyroid
Neurological
Kidney
Liver
Chi Square Analysis with population distribution above or below the mean of the total population (60.1 for Age of Diagnosis,
2.12 for Disease Duration). Mean (s.d) is in years, represents Age of Diagnosis or Disease Duration
* Control population compared to any antecedent condition population
† N represents size of population with antecedent condition of interest and control population (no antecedent conditions)
** Fisher’s exact test used due to small sample size for Age of Diagnosis and Disease Duration
‡ Fisher’s exact test used due to small sample size for Disease Duration
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Table 3. Categories of Antecedent Condition on Age of Diagnosis and Disease
Duration, Chi Square Analysis
Antecedent Condition
Cardiovascular
1
2
3
4*

Age of Diagnosis
Mean (s.d) N
P-value
62.8 (11.0)
64.8 (11.0)
63.3 (9.1)
63.5 (10.7)

762
641
508
461

<.0001
<.0001

any

63.5 (10.8)

Sole Type
Multiple Types
Amount of Conditions
1
2
3
4
5*
6‡

Disease Duration
mean (s.d.) N
P-value
584
486
393
371

0.0002
0.0011

<.0001
0.1242

1.8 (1.8)
1.7 (1.4)
1.7 (1.7)
1.7 (1.2)

1357

<.0001

1.8 (1.7)

742

<.0001

59.2 (12.5)
63.9 (10.7)

686
812

0.3806
<.0001

2.7 (2.4)
2.1 (2.0)

396
466

0.1702
0.6600

61.3 (11.3)
65.0 (10.7)
65.7 (10.0)
62.7 (9.4)
64.8 (5.5)
65.0†

747
663
530
478
456
454

<.0001
<.0001
<.0001
0.0149
0.0614
0.3935

2.1 (2.0)
1.6 (1.4)
1.4 (1.4)
2.4 (1.9)
2.5 (2.4)
-

582
502
412
380
367
-

0.01
0.0002
0.0005
0.6715
1
-

0.0196
0.2462

Autoimmune

Chi Square Analysis with population distribution above or below the mean of the total
population (60.1 for Age of Diagnosis, 2.12 for Disease Duration). Mean (s.d.) is in years,
represents Age of Diagnosis or Disease Duration
† Sample size of one
* Fisher’s exact test used due to small sample size for Age of Diagnosis and Disease Duration
‡ Fisher’s exact test used due to small sample size for Age of Diagnosis
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Table 4. Ordinal Logistic Regression Modeling of Age
of Diagnosis and Disease Duration
Model

Variable

Odds Ratio

95%
Confidence
Interval

Age of Diagnosis
Blood Pressure

0.461

0.334

0.636

Cholesterol
Diabetes

0.385
0.711

0.285
0.458

0.521
1.104

Obesity

2.268

1.494

3.443

Asthma

1.001

0.588

1.705

Arthritis

0.608

0.358

1.034

COPD

0.419

0.212

0.826

Neurological

0.303

0.072

1.279

Kidney
Liver
Thyroid

0.375
3.522
0.896

0.106
0.706
0.615

1.322
17.571
1.306

Race (Black)

1.577

1.2456

1.99767

Race (Other)

0.676

0.563

0.81

Gender (Female)

0.776

0.69235

0.87046

Disease Duration
Blood Pressure

1.06

0.705

1.595

Cholesterol

1.048

0.723

1.518

Diabetes

1.044

0.586

1.862

Obesity

1.085

0.629

1.871

Asthma

0.629

0.329

1.201

Arthritis

0.919

0.48

1.759

COPD

1.366

0.568

3.283

Neurological

0.973

0.252

3.757

Kidney

2.3

0.59

8.968

Liver

0.347

0.081

1.485

Thyroid

0.846

0.536

1.334

Race (Black)

0.624

0.464

0.837

Race (Other)
Gender (Female)

1.807
1.080

1.438
0.938

2.271
1.241

Age

1.049

1.036

1.062

Race reference group is Caucasian. Gender reference group is Male.
For age of diagnosis model, estimates above 1 lower the age of
diagnosis. For disease duration, estimates above 1 shorten the
duration.

